Procrit (epoetin alfa) Dec 2004
Audience: Oncologists, hematologists and other healthcare professionals
Ortho Biotech Products notified healthcare professionals of important changes to the safety information and dosing sections of the product labeling for Procrit. To ensure consistency with labeling for other products in this class, changes to hemoglobin rate of rise and target were made. The new prescribing information recommends that the target hemoglobin in patients with cancer should not exceed 12 grams per deciliter in men and women.
[August 13, 2004 - Letter - Ortho Biotech]